What is the difference between white matter and gray matter in the brain?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The key difference between white and gray brain matter lies in their composition, function, and impact on clinical outcomes, with gray matter damage being more relevant to clinical outcomes than white matter injury. The distinction between these two types of brain matter is crucial for understanding their roles in brain function and disease. Gray matter, which contains neuronal cell bodies, dendrites, and unmyelinated axons, is primarily responsible for processing information and generating commands, including higher cognitive functions 1. In contrast, white matter, composed mainly of myelinated axons, facilitates the rapid transmission of nerve signals between neurons, effectively forming the brain's communication network.

Some of the key points highlighting the difference and importance of gray matter over white matter in clinical contexts include:

  • Gray matter damage can occur before white matter atrophy and independently of white matter lesions 1.
  • Longitudinal studies have shown larger decreases in gray matter volumes than in white matter volumes, indicating a potentially greater impact of gray matter loss on disease progression 1.
  • The association between gray matter atrophy and disability endpoints is statistically significant, particularly in regions such as the cingulate, pre-central and post-central gyri, thalami, and basal ganglia 1.
  • Despite the regional variability, global brain volume changes, which include both gray and white matter, seem to be more strongly associated with clinical outcomes, suggesting that while gray matter is critical, the overall brain health is also a significant factor 1.

Understanding these differences is essential for the clinical management of diseases affecting the brain, such as multiple sclerosis (MS), where both gray and white matter are impacted but gray matter damage appears to have a more significant influence on the severity and progression of the disease 1.

From the Research

Difference in White and Gray Brain Matter

  • The main difference between white and gray brain matter lies in their composition and function.
  • Gray matter is composed of neuronal cell bodies and is responsible for information processing and plasticity, as shown by studies on brain function 2.
  • On the other hand, white matter is composed of myelinated axons that connect different brain regions and form functional neural circuits.
  • Recent evidence suggests that myelin, formed by oligodendrocytes, shows plastic changes depending on neuronal activity, highlighting the importance of white matter in learning and training 2.

Role of White and Gray Matter in Brain Function

  • Gray matter is involved in various higher-order cognitive functions, such as perception, attention, and memory.
  • White matter, on the other hand, plays a crucial role in facilitating communication between different brain regions and enabling the integration of information.
  • Damage to white matter, such as in multiple sclerosis, can lead to disruptions in communication between brain regions and result in cognitive and motor impairments.
  • Studies have investigated the effects of immunomodulatory drugs, such as interferon beta and glatiramer acetate, on white matter lesions and disease progression in multiple sclerosis patients 3, 4, 5, 6.

Comparison of Interferon Beta and Glatiramer Acetate

  • Interferon beta and glatiramer acetate are two disease-modifying therapies commonly used to treat relapsing-remitting multiple sclerosis.
  • Studies have compared the efficacy and safety of these two therapies, with some showing similar clinical efficacy but differing effects on MRI outcomes 3.
  • Other studies have investigated the use of glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated patients, with results suggesting that prior interferon-beta-1b treatment does not negatively influence the efficacy or safety of subsequent glatiramer acetate therapy 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Brain function and white matter].

Brain and nerve = Shinkei kenkyu no shinpo, 2015

Research

Interferon beta and glatiramer acetate therapy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.